Primary Sjögren's syndrome activity and damage indices comparison

European Journal of Clinical Investigation

Volumn 40, Issue 7, 2010, Pages 636-644

  Campar, Ana ^a   Isenberg, David A ^b  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Activity; Damage; Indices; Primary Sj gren's syndrome

Indexed keywords

COMPARATIVE STUDY; CONTENT VALIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; EULAR SJOGREN SYNDROME PATIENTS REPORTED INDEX; EULAR SS DISEASE ACTIVITY INDEX; HUMAN; INJURY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROFILE OF FATIGUE AND DISCOMFORT; PROGNOSIS; RELIABILITY; REVIEW; SCORING SYSTEM; SHORT FORM 36; SJOEGREN SYNDROME; SJOGREN SYSTEMIC CLINICAL ACTIVITY INDEX; SS DAMAGE INDEX; SS DISEASE ACTIVITY INDEX; SS DISEASE DAMAGE INDEX; VALIDATION PROCESS;

HUMANS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 77953522667     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02303.x     Document Type: Review

References (43)

1. Fox RI. Sjögren's syndrome. Lancet 2005 366: 321 331.
2. Konttinen YT, Käsna-Ronkainen L. Sjögren's syndrome: viewpoint on pathogenesis. Scand J Rheumatol 2002 116 (31 Suppl 15 22.
3. Delaleu N, Jonsson MV, Appel S, Jonsson R. New concepts in the pathogenesis of Sjögren's syndrome. Rheum Dis Clin N Am 2008 34: 833 845.
4. Nikolov NP, Illei GG. Pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol 2009 21: 465 470.
5. Lazarus MN, Robinson D, Mak V, Møller H, Isenberg DA. Incidence of cancer in a cohort of patients with primary Sjögren's syndrome. Rheumatology 2006 45: 1012 1015.
6. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002 46: 741 747.
7. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum 2004 50: 1262 1269.
8. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren's syndrome. Arch Intern Med 2004 164: 1275 1284.
9. Bowman SJ. Patient-reported outcomes including fatigue in primary Sjögren's syndrome. Rheum Dis Clin N Am 2008 34: 949 962.
10. Vitali C. Measurement of disease activity and damage in Sjögren's syndrome. Rheum Dis N Am 2008 34: 963 971.
11. Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M et al. Sjögren's Syndrome Disease Damage Index and Disease Activity Index. Arthritis Rheum 2007 56: 2223 2231.
12. Bowman SJ, Sutcliffe N, Isenberg DA, Goldblatt F, Adler M, Price E et al. Sjögren's Systemic Clinical Activity Index (SCAI)-a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. Rheumatology (Oxford) 2007 46: 1845 1851.
13. Seror R, Ravaud P, Bowman S, Baron G, Tzioufas A, Theander E et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease index in primary Sjögren's syndrome. Ann Rheum Dis 2009 doi: [Epub ahead of print].
14. Barry RJ, Sutcliffe N, Isenberg DA, Price E, Goldblatt F, Adler M et al. The Sjögren's Syndrome Damage Index-a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome. Rheumatology (Oxford) 2008 47: 1193 1198.
15. Bowman SJ, Booth DA, Platts RG, UK Sjögren's Interest Group. Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire tool. Rheumatology (Oxford) 2004 43: 758 764.
16. Strombeck B, Ekdahl C, Manthorpe R, Wikstrom I, Jacobsson L. Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 2000 29: 20 8.
17. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002 61: 554 558.
18. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas AG, Theander E et al. Development and preliminary validation of the EULAR Sjögren's syndrome disease activity index (ESSDAI): a new consensual disease activity index that detects changes accurately. Presented at the American College Rheumatology 2009 Annual Meeting, Pennsylvania, October 18.
19. Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 2009 48: 691 695.
20. Segal B, Bowman SJ, Fox PC, Vivino FB, Murukutla N, Brodscholl J et al. Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health and Quality of Life Outcomes 2009 7: 46. doi:.
21. Bowman SJ, Hamburger J, Richards A, Barry RJ, Rauz S. Patient-reported outcomes in primary Sjögren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort-Sicca Symptoms Inventory. Rheumatology (Oxford) 2009 48: 140 143.
22. Bowman SJ, Booth DA, Platts RG, Field A, Rostron J, UK Sjögren's Interest Group. Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren syndrome. J Rheumatol 2003 30: 1259 1266.
23. Sutcliffe N, Stoll T, Pyke S, Isenberg DA. Functional disability and end organ damage in patients with Systemic Lupus Erythematosus (SLE) and Sjögren's Syndrome (SS), and primary SS. J Rheumatol 1999 26: 504 507.
24. Bowman SJ. Collaborative research into outcome measures in Sjögren's syndrome. Update on disease assessment. Scand J Rheumatol 2002 116 (31 Suppl 23 7.
25. Hay EM, Thomas E, Pal B, Hajeer A, Chambers H, Silman AJ. Weak association between subjective symptoms and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis 1998 57: 20 4.
26. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005 52: 2740 2750.
27. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007 57: 310 317.
28. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N et al. Effective rituximab treatment in primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2010 62: 960 968.
29. Barendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH, Boomsma F et al. Fatigue in primary Sjögren's syndrome. Ann Rheum Dis 1998 57: 291 295.
30. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J et al. Reduction of fatigue in Sjögren's syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 2008 67: 1541 1544.
31. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005 64: 347 354.
32. Mariette X. Therapeutic potential for B-cell modulation in Sjögren's syndrome. Rheum Dis Clin N Am 2008 34: 1025 1033.
33. Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary Sjögren's syndrome. Scand J Immunol 2008 68: 554 564.
34. Walker J, Gordon T, Lester S, Downie-Doyle S, McEvoy D, Pile K et al. Increased severity of lower urinary tract symptoms and daytime somnolence in primary Sjögren's syndrome. J Rheumatol 2003 30: 2406 2412.
35. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases. Arch Intern Med 2005 165: 2337 2344.
36. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution and morbidity and mortality pf primary Sjögren's syndrome. Semin Arthritis Rheum 2000 29: 296 304.
37. Brito-Zerón P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjögren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007 46: 1359 1362.
38. Ramos-Casals M, Brito-Zerón P, Yagüe J, Akasbi M, Bautista R, Ruano M et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjögren's syndrome. Rheumatology (Oxford) 2005 44: 89 94.
39. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006 65: 796 803.
40. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in patients with primary Sjögren's syndrome. Arthritis Rheum 1996 39: 767 772.
41. Talal N, Sokoloff L, Barth WF. Extrasalivary lymphoid abnormalities in Sjögren's syndrome (reticulum-cell sarcoma, "pseudolymphoma", macroglobulinemia). Am J Med 1967 43: 50 65.
42. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM, Members of the European Concerted Action on Sjögren's Syndrome. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999 42: 1765 1772.
43. Stevens RJ, Hamburger J, Ainsworth JR, Holmes G, Bowman SJ. Flares of systemic disease in primary Sjögren's syndrome. Rheumatology (Oxford) 2005 44: 402 403.